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Introduction
Docetaxel (D) is used in combination with the human epidermal growth factor receptor 2 (HER2)-targeting antibodies pertuzumab and trastuzumab for the first-line treatment of HER2-positive metastatic breast cancer (MBC) [1] . The benefits of this now-standard regimen were established in the pivotal phase III CLEOPATRA study, in which median progression-free survival (PFS) and overall survival (OS) were significantly improved with the addition of pertuzumab (versus placebo) to trastuzumab plus D [2] [3] [4] . This regimen is also approved as a neoadjuvant treatment of HER2-positive high-risk breast cancer, including locally advanced or inflammatory disease [5, 6] .
The optimal duration of D treatment has not been established for MBC. American Society of Clinical Oncology guidelines, however, recommend $4-6 months (or longer) of chemotherapy and/or up to maximal response when used in combination with HER2-targeted therapy [7] . A minimum of 6D cycles was recommended in CLEOPATRA, but a maximum was not defined and >6 cycles were permitted per investigator discretion. Following D discontinuation, study participants could have continued treatment with trastuzumab plus pertuzumab or placebo [2] .
Because chemotherapy is associated with a detrimental impact on quality of life [8] , there is value in assessing whether longer durations of D treatment contribute to meaningful survival benefits in MBC, as treatment in this patient population is often described as palliative (with quality of life being a key consideration). The primary objective of this post hoc, exploratory analysis of CLEOPATRA study data was to evaluate the relationship between D treatment duration and clinical outcomes after accounting for HER2-targeted therapy (pertuzumab plus trastuzumab versus trastuzumab). We also evaluated the effect of adding pertuzumab to trastuzumab plus D within D duration groups.
Methods

Study design
In total, 808 patients with unresectable, locally recurrent, or metastatic HER2-positive breast cancer were enrolled in CLEOPATRA between February 2008 and July 2010. Patients were randomized to trastuzumab and D plus pertuzumab (pertuzumab arm) or trastuzumab and D plus placebo (control arm) (supplementary Figure S1 , available at Annals of Oncology online). Study methodology and primary results have been published [2] [3] [4] . The study was conducted in conformance with the principles of the Declaration of Helsinki or with the laws and regulations of the country in which the research was conducted, whichever afforded greater protection to the patient.
This post hoc analysis of D treatment duration was carried out on the safety population (n ¼ 804), which included patients who received !1 dose of any study drug. After a statistically significant increase in OS was demonstrated in the pertuzumab arm of CLEOPATRA (per a May 2012 data cut), patients randomized to placebo were allowed crossover to pertuzumab [3] . The cut-off date for data collection for the current analysis was 11 February 2014 and reflects the data cut used for the final analysis of OS in CLEOPATRA. This analysis only used data collected before crossover, except for the time-dependent Cox regression analysis that utilized all available data.
In CLEOPATRA, a minimum number of six cycles was recommended for D treatment, but not trastuzumab or pertuzumab, which were generally administered until disease progression or unacceptable toxicity. Patients who discontinued D before HER2-targeted therapy were required to complete a D discontinuation case report form separate from a study treatment discontinuation case report form, enabling clinicians to cite what they defined as 'standard practice' or 'adequate therapy' as a reason for D discontinuation.
Treatment
Patients received pertuzumab [840-mg loading dose, 420-mg maintenance dose every 3 weeks (q3w)] or placebo plus trastuzumab (8-mg/kg loading dose, 6-mg/kg maintenance dose q3w) and D. D was administered at a starting dose of 75 mg/m 2 q3w, but investigators could escalate to 100 mg/m 2 if the safety profile was acceptable after the first cycle. D dose could be reduced to 55 mg/m 2 , delayed, or discontinued if patients experienced unacceptable toxicity. If D was discontinued, patients were allowed to continue antibody therapy until disease progression, unacceptable toxicity, or withdrawal of consent. A minimum of 6D cycles was recommended in the absence of disease progression or toxicity, and >6 cycles were permitted per investigator discretion [2] .
Data analysis
For the current analysis, baseline demographics and disease characteristics, treatment exposure, discontinuation reasons, and clinical outcomes were summarized by the number of D cycles patients received (categorized as <6D, 6D, or >6D). To evaluate the primary objective, a timedependent, multivariate Cox proportional-hazards model was applied to estimate the adjusted hazard ratios (HRs) for the different categories of D cycles received after adjusting for HER2-targeted therapy. The model included three time-dependent covariates for study treatment (trastuzumab plus pertuzumab versus trastuzumab plus placebo) and two covariates for D cycle covariates (<6D versus 6D cycles and >6D versus 6D cycles), with stratification by prior treatment status and world region. The interactions of these covariates over time were also assessed. With the time-dependent study treatment covariate, the actual study treatment that patients were receiving at a given time point was considered (rather than fixing treatment assignment according to randomization). Moreover, the time-dependent D cycles covariate reflected the cumulative number of D cycles that patients had received by a given time point. As a sensitivity analysis, a time-dependent, multivariate Cox proportional-hazards model was also applied to the subset of patients who discontinued D alone due to standard practice or adequate therapy. A secondary objective of this analysis was to evaluate the effect of adding pertuzumab to trastuzumab plus D within D duration groups. The KaplanÀMeier approach was used to estimate median PFS and OS for each treatment arm within each D group. The two-sided log-rank test, stratified by prior treatment status and region, was used to compare PFS and OS between the pertuzumab and control arms within each D group. A Cox proportional-hazards model, stratified by prior treatment status and world region, was used to estimate the HR of the study treatment arm and the associated 95% confidence interval (CI) within each D group.
Results
Patient demographics and treatment exposure
Among the 804 patients included in the safety population, 119 received <6D cycles, 210 received 6D cycles, and 475 received >6D cycles. Baseline demographics and disease characteristics were generally similar across treatment arms within each D duration group (Table 1) . While several imbalances were apparent by world region, Eastern Cooperative Oncology Group (ECOG) performance status, disease type, and hormone receptor status, the presence of some disparities was not unexpected in this post hoc analysis. The number of D cycles received was similar within each D cycle group by treatment arm, with an overall median of 8 cycles in each arm (median of 3 cycles in each arm in the <6D group and 10 cycles in each arm in the >6D group) ( Table 2 ). Median D dose intensity was comparable across treatment arms (range 24.5-25.0 mg/m 2 per week). Patients in the <6D group received a median of three cycles of study treatment in the placebo and pertuzumab arms; the median duration of study treatment was 2.1 months in both treatment arms. In the 6D group, patients in the control arm received a median of 15 treatment cycles with a median treatment duration of 10.5 months; the corresponding values in the pertuzumab arm were 24 cycles and 16.7 months, respectively. In the >6D group, patients in the control arm received a median of 19 cycles with a median treatment duration of 13.8 months, while patients in the pertuzumab arm received 28 cycles with a median treatment duration of 19.4 months ( Table 2) .
Treatment discontinuation
In the <6D group, 15.9% of patients in the control arm and 23.2% in the pertuzumab arm discontinued D alone (before ending HER2-targeted therapy), all due to adverse events (AEs) or Table 1 . Baseline demographic and disease characteristics <6D cycles (n 5 119) 6D cycles (n 5 210) >6D cycles (n 5 475) 
Number of study treatment cycles, median (range) intercurrent illness (Table 3 ). The most common AEs leading to D discontinuation alone were neutropenia (2 patients, 3.2%), drug hypersensitivity (2 patients, 3.2%), and hypersensitivity (2 patients, 3.2%) in the control arm, and diarrhea (3 patients, 5.4%) and toxic hepatitis (2 patients, 3.6%) in the pertuzumab arm. Most patients in the 6D and the >6D groups who discontinued D continued HER2-targeted treatment. In the 6D group, this included 79.2% of patients in the control arm and 89.5% in the pertuzumab arm. The most frequent reason for D discontinuation alone was 'standard practice' (defined by the investigator as the number of cycles considered to be routine) in both the control (47.4%) and pertuzumab arms (57.8%). A total of 31.6% and 13.7% of patients in the control and pertuzumab treatment arms, respectively, discontinued D due to AE/intercurrent illness. The most common AEs leading to D discontinuation alone were peripheral neuropathy (5 patients, 5.2%) in the control arm, and neutropenia (2 patients, 1.8%), peripheral neuropathy (2 patients, 1.8%), and fatigue (2 patients, 1.8%) in the pertuzumab arm.
In the >6D group, 73.8% of patients in the control arm and 80.3% in the pertuzumab arm continued HER2-targeted therapy after discontinuing D. The most common reasons for D discontinuation alone in the control arm were 'standard practice' (37.1%) and AE/intercurrent illness (34.3%). In the pertuzumab arm, patients most often discontinued due to AE/intercurrent illness (37.7%) or because the investigator considered the patient to have received 'adequate therapy' (defined by the investigator as sufficient therapy or response) (30.9%). The most frequent AEs leading to D discontinuation alone were edema (12 patients, 5.1%) in the control arm and peripheral neuropathy (13 patients, 5.5%) in the pertuzumab arm.
In the <6D group, 100% of patients in the control arm and 96.4% of patients in the pertuzumab arm had discontinued all study treatment by data cut-off. In the 6D group, 88.5% and 85.1% of patients withdrew from treatment, respectively. The corresponding values in the >6D group were 83.1% and 78.6%, respectively. The most common reason for study treatment discontinuation across all D groups and treatment arms was insufficient therapeutic response (i.e. disease progression).
Clinical outcomes
After adjusting for the effect of study treatment (pertuzumab versus placebo: PFS HR ¼ 0.61, 95% CI 0.51-0.74, P < 0.0001 and OS HR ¼ 0.60, 95% CI 0.49-0.74, P < 0.0001), time-dependent Cox regression analysis showed no statistically significant improvement in PFS (HR ¼ 0.80, 95% CI 0.63-1.01, P ¼ 0.0640) or Table 3 . Reasons for treatment discontinuation <6D cycles (n 5 119) 6D cycles (n 5 210) >6D cycles (n 5 475) Patients who discontinued D alone due to 'standard practice' or 'adequate therapy' (n ¼ 330) rather than for toxicity or lack of efficacy would be a relevant, relatively homogeneous population in which to evaluate the effects of extended D treatment on clinical outcomes. All patients in this subgroup had received !6 cycles of D. After adjusting for HER2-targeted therapy, timedependent Cox regression analysis showed no statistically significant improvements in PFS (HR ¼ 0.90, 95% CI 0.65-1.26) or OS (HR ¼ 0.78, 95% CI 0.54-1.12) with >6D versus 6D cycles.
Compared with placebo, the addition of pertuzumab to trastuzumab plus D significantly improved PFS, regardless of whether patients received <6D, 6D, or >6D cycles (Figure 1) . The addition of pertuzumab also significantly improved OS in the <6D and >6D groups. Although an HR of 0.70 (95% CI 0.47-1.04) was observed in the 6D group, the results were not statistically significant (P ¼ 0.0790).
Discussion
In this post hoc analysis of patients with HER2-positive MBC participating in CLEOPATRA, the addition of pertuzumab to trastuzumab and D provided consistent improvements in clinical outcomes, irrespective of the duration of D treatment. After accounting for the benefits of adding pertuzumab rather than placebo to trastuzumab plus D, the receipt of more than six cycles of D was not associated with statistically significant additional clinical benefit compared with the recommended minimum of six cycles (PFS HR ¼ 0.80, 95% CI 0.63-1.01, P ¼ 0.0640; OS HR ¼ 0.88, 95% CI 0.69-1.12, P ¼ 0.3073). Similar results were observed in patients with >6D versus 6D cycles who discontinued D due to 'standard practice' or 'adequate therapy' (after adjusting for HER2-targeted therapy, PFS HR ¼ 0.90, 95% CI 0.65-1.26; OS HR ¼ 0.78, 95% CI 0.54-1.12). As this subgroup omits patients who discontinued D due to toxicity or disease progression, it is expected to reflect more closely patients who discontinue D as part of standard clinical practice.
In CLEOPATRA, receipt of fewer than 6D cycles was associated with poorer PFS and OS compared with 6D cycles. Patients in the <6D group discontinued all study treatment after a median of only 2.1 months (primarily due to disease progression or AEs) compared with 10.5-16.7 months in the 6D group and 13.8-19.4 months in the >6D group. The poorer outcomes observed in the <6D group were likely attributable to the discontinuation of all study treatment following early disease progression. Nevertheless, patients in the <6D group who received pertuzumab experienced statistically significant benefits in PFS and OS relative to patients who received placebo. Compared with patients treated with trastuzumab plus D, those who also received pertuzumab had significantly improved PFS across all D duration groups and improved OS in the <6D and >6D groups; these findings are consistent with the overall results from CLEOPATRA [2] [3] [4] . D exposure was similar between treatment arms within each D duration group, suggesting that the relative improvements observed in the pertuzumab arms are not driven by higher exposure to D.
The duration of chemotherapy (in the absence of concurrent targeted therapy) has been examined in several clinical trials. In one study of patients with MBC, eight additional cycles of paclitaxel following first-line treatment with six to eight cycles of paclitaxel plus epirubicin or doxorubicin did not confer PFS or OS benefits [9] . In contrast, another study noted that extended first-line treatment with paclitaxel plus gemcitabine beyond six cycles improved both PFS and OS compared with six cycles [10] . This is supported by a meta-analysis that found a longer duration of chemotherapy to result in significant improvements in PFS and OS in patients with MBC [11] . While HRs for 6D versus >6D cycles appeared to numerically favor >6D cycles for PFS and OS in this analysis, consistent with the results of the meta-analysis [11] , the differences were not significant. Of note, the metaanalysis lacked studies assessing D or HER2-targeted treatments. A reasonable assumption could be made that the impact of extended chemotherapy differs by the precise nature of the regimen. The absence of a significant benefit with >6D (versus 6D) cycles suggests that, as part of a regimen including pertuzumab and trastuzumab, discontinuation of D treatment after six cycles does not appear to confer an overall negative impact on patient outcomes. This analysis provides the first methodical insights regarding the impact of D duration on outcomes in patients with HER2-positive MBC receiving standard first-line treatment. Treatment guidelines for HER2-positive MBC recommend the use of D or paclitaxel with pertuzumab plus trastuzumab [1] . Preliminary results from the phase III PERUSE study, which assesses the safety and efficacy of investigator's choice of taxane with trastuzumab plus pertuzumab for the first-line treatment of locally recurrent breast cancer or MBC, indicated that median treatment duration was similar for D (3.8 months), paclitaxel (4.2 months), and nab-paclitaxel (3.9 months) [12] .
This exploratory analysis is limited by several factors, including moderate imbalances in patient characteristics between D duration groups, small patient numbers in some subgroups, and the categorization of patients based on non-randomized, post-baseline values (i.e. duration of D exposure). Therefore, these results should be interpreted with caution and confirmed in a randomized study. 
